Calithera Biosciences Crecimiento futuro

Future controles de criterios 0/6

Actualmente no disponemos de suficiente cobertura de analistas para prever el crecimiento y los ingresos de Calithera Biosciences.

Información clave

n/a

Tasa de crecimiento de los beneficios

n/a

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	28.5%
Tasa de crecimiento de los ingresos	n/a
Rentabilidad financiera futura	n/a
Cobertura de analistas	None
Última actualización	n/a

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

We Think Calithera Biosciences (NASDAQ:CALA) Needs To Drive Business Growth Carefully

Dec 17

We Think Calithera Biosciences (NASDAQ:CALA) Needs To Drive Business Growth Carefully

Aug 27

The Upcoming Calithera Cystic Fibrosis Data Could Be Significant

Aug 03

Calithera Biosciences Investor Presentation - Slideshow

May 08

Is Calithera Biosciences (NASDAQ:CALA) In A Good Position To Deliver On Growth Plans?

May 02

What Kind Of Investors Own Most Of Calithera Biosciences, Inc. (NASDAQ:CALA)?

Mar 10

Calithera Biosciences, Inc. (NASDAQ:CALA) Shares Could Be 46% Below Their Intrinsic Value Estimate

Jan 17

Calithera sinks as telaglenastat fails in kidney cancer study; lowers headcount

Jan 04

Companies Like Calithera Biosciences (NASDAQ:CALA) Are In A Position To Invest In Growth

Dec 13

Calithera Biosciences Poised For Long-Term Success

Nov 25

Calithera Biosciences (CALA) Investor Presentation - Slideshow

Nov 06

En esta sección solemos presentar previsiones de crecimiento de ingresos y beneficios basadas en las estimaciones por consenso de analistas profesionales para ayudar a los inversores a comprender la capacidad de la empresa para generar beneficios. Pero como Calithera Biosciences no ha proporcionado suficientes datos anteriores y no dispone de previsiones de analistas, sus beneficios futuros no pueden calcularse de forma fiable extrapolando datos anteriores o utilizando las previsiones de los analistas.

Es una situación poco común, ya que el 97% de las empresas disponibles en SimplyWall St sí disponen de datos financieros anteriores.

Previsiones de crecimiento de beneficios e ingresos

OTCPK:CALA - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2022	N/A	-21	-44	-44	N/A
9/30/2022	N/A	-84	-61	-61	N/A
6/30/2022	7	-85	-61	-60	N/A
3/31/2022	10	-107	-60	-60	N/A
12/31/2021	10	-115	-66	-66	N/A
9/30/2021	10	-68	-64	-64	N/A
6/30/2021	3	-80	-72	-72	N/A
3/31/2021	N/A	-86	-79	-79	N/A
12/31/2020	N/A	-90	-84	-84	N/A
9/30/2020	N/A	-89	-80	-80	N/A
6/30/2020	N/A	-87	-83	-83	N/A
3/31/2020	N/A	-91	-85	-85	N/A
12/31/2019	N/A	-90	-79	-79	N/A
9/30/2019	N/A	-88	-74	-74	N/A
6/30/2019	N/A	-86	-71	-71	N/A
3/31/2019	17	-65	-71	-71	N/A
12/31/2018	22	-55	-65	-65	N/A
9/30/2018	30	-46	-63	-62	N/A
6/30/2018	37	-33	-58	-57	N/A
3/31/2018	27	-35	-38	-36	N/A
12/31/2017	26	-28	13	14	N/A
9/30/2017	19	-26	15	16	N/A
6/30/2017	11	-29	20	21	N/A
3/31/2017	4	-34	12	12	N/A
12/31/2016	N/A	-38	-31	-31	N/A
9/30/2016	N/A	-37	N/A	-32	N/A
6/30/2016	N/A	-37	N/A	-32	N/A
3/31/2016	N/A	-34	N/A	-30	N/A
12/31/2015	N/A	-33	N/A	-30	N/A
9/30/2015	N/A	-31	N/A	-24	N/A
6/30/2015	N/A	-28	N/A	-24	N/A
3/31/2015	N/A	-25	N/A	-22	N/A
12/31/2014	N/A	-22	N/A	-19	N/A
9/30/2014	N/A	-19	N/A	-19	N/A
6/30/2014	N/A	-17	N/A	-16	N/A
3/31/2014	N/A	-14	N/A	-14	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Datos insuficientes para determinar si el crecimiento previsto de los beneficios de CALA es superior a la tasa de ahorro (2.6%).

Beneficios vs. Mercado: Datos insuficientes para determinar si se prevé que los beneficios de CALA crezcan más rápidamente que el mercado US

Beneficios de alto crecimiento: Datos insuficientes para determinar si se espera que los beneficios de CALA crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: No hay datos suficientes para determinar si se prevé que los ingresos de CALA crezcan más rápidamente que el mercado de US.

Ingresos de alto crecimiento: No hay datos suficientes para determinar si se prevé que los ingresos de CALA crezcan a un ritmo superior a 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de CALA se prevé que sea elevada dentro de 3 años.

Calithera Biosciences Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target decreased to US$12.36

Price target decreased to US$2.38

Price target lowered to US$10.10

Recent updates

Calithera Biosciences, Inc. Launches the Cala kIQ System, Offering Meaningful Tremor Relief for Patients with Essential Tremor and Now Parkinson’s Disease

Calithera Biosciences, Inc.(NasdaqGS:CALA) dropped from NASDAQ Composite Index

Calithera Biosciences Board Approves Dissolution and Liquidation

Calithera Biosciences, Inc. Announces Executive Departures

Price target decreased to US$12.36

Calithera Biosciences, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Calithera Biosciences, Inc. Receives U.S. Food & Drug Administration Fast Track Designation for Sapanisertib for the Treatment of NRF2-Mutated Squamous Lung Cancer

Calithera gains 16% as FDA awards Fast Track status for lung cancer candidate

Calithera rises 8% after HC Wainwright upgrades rating to buy

Calithera Biosciences, Inc. announced delayed 10-Q filing

Is Calithera Biosciences (NASDAQ:CALA) In A Good Position To Invest In Growth?

Calithera Biosciences, Inc. to Report Q2, 2022 Results on Aug 15, 2022

Calithera Biosciences, Inc. Shares Progress in Sapanisertib and Mivavotinib Clinical Programs at Upcoming Lung Cancer and Lymphoma Conferences

Calithera Biosciences Announces First Patient Enrolled in Phase 2 Clinical Trial of Sapanisertib in Relapsed/Refractory Nrf2 (Nfe2l2)-Mutated Squamous Non-Small Cell Lung Cancer

Calithera Biosciences, Inc. Announces First Patient Enrolled in Phase 2 Clinical Trial of Mivavotinib in Relapsed/Refractory non-GCB (ABC) Diffuse Large B-Cell Lymphoma

Calithera Biosciences, Inc. to Report Q1, 2022 Results on May 10, 2022

Price target decreased to US$2.38

Calithera Biosciences, Inc. Receives A Written Notice from the Listing Qualifications Staff of the Nasdaq

We Think Calithera Biosciences (NASDAQ:CALA) Needs To Drive Business Growth Carefully

Independent Director recently bought US$172k worth of stock

Calithera Biosciences, Inc. to Present Telaglenastat KEAPSAKE Trial in Progress Poster at the IASLC 2021 World Conference on Lung Cancer

We Think Calithera Biosciences (NASDAQ:CALA) Needs To Drive Business Growth Carefully

The Upcoming Calithera Cystic Fibrosis Data Could Be Significant

Calithera Biosciences, Inc.(NasdaqGS:CALA) dropped from Russell 3000E Growth Index

Calithera Biosciences, Inc. Presents Final Data from Calithera Biosciences’ Phase 2 CANTATA Study in Renal Cell Carcinoma Presented at 2021 ASCO Annual Meeting

Calithera Biosciences Investor Presentation - Slideshow

Is Calithera Biosciences (NASDAQ:CALA) In A Good Position To Deliver On Growth Plans?

Calithera Biosciences, Inc. Announces Results from the Cantata Clinical Study Will Be Shared in an Oral Presentation At the American Society of Clinical Oncology

Chief Business Officer has left the company

Calithera Biosciences, Inc. Announces Resignation of Curtis Hecht, Chief Business Officer, Effective April 2, 2021

Calithera Biosciences, Inc. to Report Q4, 2020 Results on Mar 16, 2021

What Kind Of Investors Own Most Of Calithera Biosciences, Inc. (NASDAQ:CALA)?

Calithera Biosciences, Inc. Promotes Stephanie Wong to Secretary and Principal Financial and Accounting Officer

Calithera Biosciences, Inc. (NASDAQ:CALA) Shares Could Be 46% Below Their Intrinsic Value Estimate

Calithera Biosciences, Inc. Reports CANTATA Study of Telaglenastat in Renal Cell Carcinoma Did Not Achieve Primary Endpoint

New 90-day low: US$2.72

Price target lowered to US$10.10

Calithera sinks as telaglenastat fails in kidney cancer study; lowers headcount

Companies Like Calithera Biosciences (NASDAQ:CALA) Are In A Position To Invest In Growth

New 90-day high: US$5.03

Calithera Biosciences Poised For Long-Term Success

New 90-day high: US$4.60

Calithera Biosciences, Inc. Presents New Preclinical Data for CB-668 at Society for Immunotherapy of Cancer (SITC) 2020 Annual Meeting

Calithera Biosciences (CALA) Investor Presentation - Slideshow

Calithera Biosciences, Inc. Announces Expansion of Ongoing Clinical Trial Evaluating Telaglenastat in Combination with Palbociclib (Ibrance)

Calithera Biosciences, Inc. to Report Q3, 2020 Results on Nov 05, 2020

Calithera Biosciences, Inc. Announces Poster Detailing the Trial Design of A Phase 1B Study of Cb-280

Calithera Biosciences, Inc. Announces Treatment of the First Patient in Randomized Phase 2 Non-Small Cell Lung Cancer

New 90-day low: US$3.43

New 90-day low - US$3.91

Calithera Biosciences, Inc. to Report Q2, 2020 Results on Aug 10, 2020

New 90-day low - US$4.94

Calithera Biosciences, Inc.(NasdaqGS:CALA) dropped from Russell Microcap Value Index

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento